These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://nicolexhkh913588.blogerus.com/60903028/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide